RT Journal Article
SR Electronic
T1 Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.25.20161661
DO 10.1101/2020.07.25.20161661
A1 Garzon-Chavez, Daniel
A1 Romero-Alvarez, Daniel
A1 Bonifaz, Marco
A1 Gaviria, Juan
A1 Mero, Daniel
A1 Gunsha, Narcisa
A1 Perez, Asiris
A1 Garcia, María
A1 Espejo, Hugo
A1 Espinosa, Franklin
A1 Ligña, Edison
A1 Espinel, Mauricio
A1 Quentin, Emmanuelle
A1 Teran, Enrique
A1 Mora, Francisco
A1 Reyes, Jorge.
YR 2020
UL http://medrxiv.org/content/early/2020/07/27/2020.07.25.20161661.abstract
AB The World Health Organization (WHO) declared coronavirus disease-2019 (COVID-19) a global pandemic on March 11th. In Ecuador, the first case of COVID-19 was recorded on February 29th. Despite efforts to control its spread, SARS-CoV-2 overrun the Ecuadorian public health system which became one of the most affected in Latin America with 22,719 cases reported up to April, 24th. Public health control measures, including social distancing and lockdowns, were implemented at different times in the biggest cities of the country: Guayaquil and Quito. The Hospital General del Sur de Quito (HGSQ) had to transition from a general to a specific COVID-19 health center in a short period of time to fulfill the health demand from patients with respiratory afflictions. Here, we summarized the implementations applied in the HGSQ to become a COVID-19 exclusive hospital, including the rearrangement of hospital rooms and a triage strategy based on a severity score calculated through an artificial intelligence (AI)-assisted chest computed tomography (CT). Moreover, we present clinical, epidemiological, and laboratory data from 75 laboratory tested COVID-19 patients, which represent the first outbreak of Quito city.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has not fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was review and approved by the IRB at Universidad San Francisco de Quito (2020-023M).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Data is available